Venus Remedies gets marketing approval from Israel, Colombia for two oncology drugs 

Venus Remedies has secured marketing authorisation for docetaxel from Israel and cytarabine from Colombia. While docetaxel, an antineoplastic agent, is beneficial in the treatment of breast, prostate, head, neck and non-small cell lung cancer, cytarabine is useful in acute non-lymphocytic leukaemia, acute lymphocytic leukaemia and chronic myelocytic leukaemia.

Israel’s pharma market, valued at about $5 billion, is projected to grow at a five-year compound annual growth rate (CAGR) of 4.2 per cent up to 2026. The marketing authorisation for cytarabine from Colombia, on the other hand, marks a significant expansion of Venus Remedies in the Latin American market. Colombia, the third-largest pharma market in South America is projected to grow at a five-year CAGR of 3.1 per cent up to 2026.